It is not the quantity, but the quality and validity of scientific studies that is of importance for regulatory safety assessments. During the past 15 years, the European authorities carried out several risk assessments of BPA, each time including all the scientific evidence that appeared since their previous assessment, altogether covering thousands of studies,  also including all the small or exploratory studies many of which claim to see an effect. However, the authorities noted several methodological, statistical or other shortcomings in many of these studies, and they are thus often not taken into account for regulatory risk assessment.